<DOC>
	<DOC>NCT01655030</DOC>
	<brief_summary>The purpose of this study is to determine whether creatine monohydrate is effective as an adjuvant treatment for bipolar depression.</brief_summary>
	<brief_title>Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Individuals eligible for the study will be adults aged 18 to 60 years of age who met DSMIV criteria assessed by the SCID (Structural Clinical Interview for DSMIV) for type I bipolar disorder, current episode depressed. Patients who have scored &gt; 19 on the MontgomeryAsberg Depression Rating Scale (MADRS) will be included, although more than two weeks of treatment with lithium (serum level&gt; 0.8 mEq / L), valproate (serum levels&gt; 50 mg / L) or quetiapine (300600mg/dia dose) or drug combination. Antipsychotics, anticonvulsants, benzodiazepines, and thyroid supplementation will be allowed if the dose has remained stable over the past two weeks. Antidepressants will be allowed if the dosage has remained stable for 4 weeks. Subjects with substance abuse within 2 weeks before inclusion or substance dependence up to 2 months will not be included. Other exclusion criteria will be: diagnosis of schizophrenia, dementia, delirium, epilepsy, mental retardation, clinically unstable medical illnesses, preexisting renal disease, history of hypersensibility to creatine. Not included are individuals at high risk for suicidal or homicidal behavior or selfmutilation will not be included. Women with gestational potential can only be included if they are using reliable contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>